Duchenne Muscular Dystrophy Epidemiology Forecast

DelveInsight's 'Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Duchenne Muscular Dystrophy Understanding

The DelveInsight Duchenne Muscular Dystrophy epidemiology report gives a thorough understanding of the Duchenne Muscular Dystrophy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Duchenne Muscular Dystrophy in the US, Europe, and Japan. The report covers the detailed information of the Duchenne Muscular Dystrophy epidemiology scenario in seven major countries (US, EU5, and Japan).


Duchenne Muscular Dystrophy Epidemiology Perspective by DelveInsight

The Duchenne Muscular Dystrophy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Duchenne Muscular Dystrophy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Duchenne Muscular Dystrophy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Duchenne Muscular Dystrophy Detailed Epidemiology Segmentation

The Duchenne Muscular Dystrophy epidemiology covered in the report provides historical as well as forecasted Duchenne Muscular Dystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Duchenne Muscular Dystrophy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Duchenne Muscular Dystrophy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Duchenne Muscular Dystrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Duchenne Muscular Dystrophy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Duchenne Muscular Dystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Duchenne Muscular Dystrophy
  • The report provides the segmentation of the Duchenne Muscular Dystrophy epidemiology


Report Highlights

  • 11-Year Forecast of Duchenne Muscular Dystrophy epidemiology
  • 7MM Coverage
  • Total Cases of Duchenne Muscular Dystrophy
  • Total Cases of Duchenne Muscular Dystrophy according to segmentation
  • Diagnosed cases of Duchenne Muscular Dystrophy


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Duchenne Muscular Dystrophy?
  • What are the key findings pertaining to the Duchenne Muscular Dystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Duchenne Muscular Dystrophy across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Duchenne Muscular Dystrophy?
  • What are the currently available treatments of Duchenne Muscular Dystrophy?


Reasons to buy

  • The Duchenne Muscular Dystrophy Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Duchenne Muscular Dystrophy market
  • Quantify patient populations in the global Duchenne Muscular Dystrophy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Duchenne Muscular Dystrophy therapeutics in each of the markets covered
  • Understand the magnitude of Duchenne Muscular Dystrophy population by its epidemiology
  • The Duchenne Muscular Dystrophy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Duchenne Muscular Dystrophy

3. Duchenne Muscular Dystrophy: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Duchenne Muscular Dystrophy Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Duchenne Muscular Dystrophy Treatment and Management

6.2. Duchenne Muscular Dystrophy Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Duchenne Muscular Dystrophy Epidemiology in 7MM (2017-2030)

Table 2 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Duchenne Muscular Dystrophy Epidemiology in the United States (2017-2030)

Table 4 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Duchenne Muscular Dystrophy Epidemiology in Germany (2017-2030)

Table 6 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Duchenne Muscular Dystrophy Epidemiology in France (2017-2030)

Table 8 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Duchenne Muscular Dystrophy Epidemiology in Italy (2017-2030)

Table 10 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Duchenne Muscular Dystrophy Epidemiology in Spain (2017-2030)

Table 12 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Duchenne Muscular Dystrophy Epidemiology in the United Kingdom (2017-2030)

Table 14 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Duchenne Muscular Dystrophy Epidemiology in Japan (2017-2030)

Table 16 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Duchenne Muscular Dystrophy Epidemiology in 7MM (2017-2030)

Figure 2 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Duchenne Muscular Dystrophy Epidemiology in the United States (2017-2030)

Figure 4 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Duchenne Muscular Dystrophy Epidemiology in Germany (2017-2030)

Figure 6 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Duchenne Muscular Dystrophy Epidemiology in France (2017-2030)

Figure 8 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Duchenne Muscular Dystrophy Epidemiology in Italy (2017-2030)

Figure 10 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Duchenne Muscular Dystrophy Epidemiology in Spain (2017-2030)

Figure 12 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Duchenne Muscular Dystrophy Epidemiology in the United Kingdom (2017-2030)

Figure 14 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Duchenne Muscular Dystrophy Epidemiology in Japan (2017-2030)

Figure 16 Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report


  • Tags:
  • Duchenne Muscular Dystrophy Epidemi...
  • Duchenne Muscular Dystrophy
  • Duchenne Muscular Dystrophy Pipeli...
  • Duchenne Muscular Dystrophy Compan...
  • Duchenne Muscular Dystrophy preval...
  • Duchenne Muscular Dystrophy incide...
  • Duchenne Muscular Dystrophy patien...
  • Duchenne Muscular Dystrophy treatm...

Forward to Friend

Need A Quote